Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?

被引:4
作者
Saposnik, Gustavo [1 ,3 ]
Sotoca, Javier [4 ]
Sempere, Angel P. [5 ]
Candeliere-Merlicco, Antonio [6 ]
Diaz-Abos, Paola [7 ]
Tobler, Philippe N. [1 ]
Terzaghi, Maria [2 ]
Maurino, Jorge [7 ]
机构
[1] Univ Zurich, Dept Econ, Lab Social & Neural Syst Res, Zurich, Switzerland
[2] Univ Toronto, Decis Neurosci Unit, Li Ka Shing Inst, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Neurol, St Michaels Hosp, Toronto, ON, Canada
[4] Hosp Univ Mutua Terrassa, Dept Neurol, Terrassa, Spain
[5] Hosp Gen Univ Alicante, Dept Neurol, Alicante, Spain
[6] Hosp Rafael Mendez, Dept Neurol, Lorca, Spain
[7] Roche Farma, Med Dept, Madrid, Spain
关键词
Multiple sclerosis; Status quo bias; Therapeutic inertia; Decision-making; Disease-modifying therapy; DECISION-MAKING; SYMPTOMSCREEN; PEOPLE; RISK;
D O I
10.1016/j.msard.2020.102354
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Status quo (SQ) bias is defined as patient's tendency to continue taking a previously selected but inferior therapeutic option. Objective: To assess the presence of SQ bias and its associated factors in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A multicenter, non-interventional study involving 211 patients with RRMS was conducted. Participants answered questions regarding risk preferences and management of simulated MS case-scenarios. The SymptoMScreen (SMSS) questionnaire was used to assess the perception of severity from the patients' perspective. SQ bias was defined as patients' preference to maintain the current treatment despite evidence of disease activity. Mixed linear models adjusting for clustering assessed the association of candidate predictors with the outcome of interest. Results: The mean age (SD) was 39.1 (9.5) years and 70.6% were women. SQ bias was observed in 74.4% (n=161) participants. Univariate analysis showed that SMSS score was associated with SQ bias (OR 1.04; 95% CI 1.01-1.07). Mixed linear regression models suggest that for every point increase in SMSS, there was a 4% increase in the likelihood of SQ bias (beta 0.04; 95%CI 0.015-0.06; p < 0.002). Among the different symptomatic dimensions included in the SMSS, only vision impairment (beta 0.32; 95%CI 0.05-0.50) and depression (beta 0.29; 95%CI 0.006-0.58) remained associated with SQ bias in the multivariate analysis. There was no association between participants' risk preferences and SQ bias. Conclusions: Unwillingness to pursue treatments that are more effective is a common phenomenon affecting over 7 out of 10 patients with RRMS. This phenomenon appears to be driven by patients' negative self-perception of their clinical status.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Dietary habits and selenium, glutathione peroxidase and total antioxidant status in the serum of patients with relapsing-remitting multiple sclerosis
    Socha, Katarzyna
    Kochanowicz, Jan
    Karpinska, Elzbieta
    Soroczynska, Jolanta
    Jakoniuk, Marta
    Mariak, Zenon
    Borawska, Maria H.
    [J]. NUTRITION JOURNAL, 2014, 13
  • [22] Dietary habits and selenium, glutathione peroxidase and total antioxidant status in the serum of patients with relapsing-remitting multiple sclerosis
    Katarzyna Socha
    Jan Kochanowicz
    Elżbieta Karpińska
    Jolanta Soroczyńska
    Marta Jakoniuk
    Zenon Mariak
    Maria H Borawska
    [J]. Nutrition Journal, 13
  • [23] Clinical features of relapsing-remitting multiple sclerosis prognostic factors
    Fernández-Fernández, O
    [J]. REVISTA DE NEUROLOGIA, 2002, 35 (11) : 1067 - 1073
  • [24] The nutritional status of relapsing-remitting multiple sclerosis (RRMS) patients compared to that of healthy people: a Turkish hospital-based study
    Atuk Kahraman, Tutku
    Yilmaz, Muge
    Yetkin, Mehmet Fatih
    Mirza, Meral
    [J]. NUTRITIONAL NEUROSCIENCE, 2022, 25 (11) : 2279 - 2287
  • [25] Therapeutic Goals of Baseline and Escalation Therapy for Relapsing-Remitting Multiple Sclerosis
    Gold, R.
    Hartung, H. -P.
    Stangel, M.
    Wiendl, H.
    Zipp, F.
    [J]. AKTUELLE NEUROLOGIE, 2012, 39 (07) : 342 - 350
  • [26] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [27] Cognitive Impairment in Patients with Early Relapsing-Remitting Multiple Sclerosis
    Keklikoglu, Hava Doenmez
    Yoldas, Tahir Kurtulus
    Zengin, Oezkan
    Banu Solak, Elif
    Keskin, Selda
    [J]. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2010, 47 (02): : 88 - 90
  • [28] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [29] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [30] Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis
    Bartnik, Pawel
    Wielgos, Aleksandra
    Kacperczyk, Joanna
    Pisarz, Katarzyna
    Szymusik, Iwona
    Podlecka-Pietowska, Aleksandra
    Zakrzewska-Pniewska, Beata
    Wielgos, Miroslaw
    [J]. BRAIN AND BEHAVIOR, 2017, 7 (06):